- Visibility 218 Views
- Downloads 67 Downloads
- Permissions
- DOI 10.18231/j.ijirm.2019.029
-
CrossMark
- Citation
Adverse effects of first line anti-tubercular drugs on patients taking directly observed treatment short course chemotherapy
- Author Details:
-
Arjun H *
Background: The World Health Organization (WHO) TB statistics for India for 2017 gives an estimated incidence of 2.8 million cases of TB for India out of a global incidence of 9.6 million. Tuberculosis (TB) is one of the common problems in every part of the world. India is the country with the highest burden of TB. The highest burden is carried by people who already face socio-economic challenges: migrants, refugees, prisoners, miners and others working and living in risk-prone settings, and marginalized women, children and older people. Anti tuberculosis treatment (ATT) is an effective treatment strategy for TB. As with all good things comes bad, ATT is associated with adverse effects, so it is very important to identify these adverse effects at the earliest, treat them and improve compliance. Hence this study intends to find out the occurrence of side effects of anti-tuberculosis drugs in patients registered under DOTS in our hospital. The main objectives of the study was to study the adverse drug effects of first line antituberculosis drugs in patients started on DOTS under RNTCP.
Methodology: Pulmonary tuberculosis patients who were started on Antituberculosis drugs under DOTS were clinically observed for adverse drug reactions (ADR) during the course of the treatment.
Results: Out of the 50 patients selected for this study, 30 patients developed at least one or more types of ADR and a total of 9 types of adverse drug reactions were observed. The most common symptom ADR observed in this study were gastrointestinal symptoms like nausea (28%), vomiting (13%), loss of taste (11%), dyspepsia (6%) and abdominal pain (9%), diarrhea (2%), jaundice (3%), others were malaise (9%) and skin rash (1%). The mean onset of the adverse drug effects were observed within 7 days and mean duration of the adverse drug effects were seen up to 2 months after start of ATT.
Conclusions: This study showed that DOTS treatment is an effective and safe treatment strategy as most of the adverse drug reactions noted were of a mild variety (Hartwig’s scale level 1) and were treated with symptomatic medications. Gastrointestinal symptoms were the most common type of ADR and most of the symptoms subsided within the intensive phase of the treatment.
Keywords: Anti Tuberculosis treatment; Adverse drug reaction; Tuberculosis.
References
- TB India 2017- RNTCP status Report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110011,2017:p9. http://tbcindia.org
- TB India 2017- RNTCP status Report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110011,2017:p20. http://www.tbcindia.org
- Govt of India (2010), TB India 2010, RNTCP Annual Status Report. (Accessed on 02-08-2018) http://www.tbcindia.org
- WHO (2010), Treatment of Tuberculosis Guidelines, 4th Ed. (Accessed on 25-08-2018)WHO reference number: WHO/HTM/TB/2009.420
- Park K. Park’s Textbook of Preventive and Social Medicine. 23 rd ed. Jabalpur: M/s Banarsidas Bhanot Publisher, 2015. p.176-202.
- Revised National Tuberculosis Programme Training Module For Medical Practitioners. Central TB Division, Directorate General of Health Service/ Ministry Of Health and Family Welfare Niaman Bhawan, New Delhi, 2005.
- Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, Jain SK, et al. Adverse Drug Reactions Observed during DOTS. J Commun Dis 2004;36(4):251-9.
- Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-4.
- Dhingra VK. Tuberculosis: Treatment and Prevention. 2008. Indian J Tuberc 2009:56:77-81.
- Tak DK, Acharya LD, Gowrinath K, Rao Padma G M, Subish P. Safety Evaluation of Antitubercular Therapy Under Revised National Tuberculosis Control Programme In India. J Clin Diagn Res 2009;3:1395-1401.
- Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30.
- Hartwig SC, Siegel J and Schneider PJ. Preventability and Severity Assessment in Reporting Adverse Drug Reactions. Am J Hosp Pharm 1992;49:2229-32.
- Kishore PV, Subish P, Pradip O, Shankar PR. Pattern of Adverse Drug Reactions Experienced by Tuberculosis Patients in a Tertiary Care Teaching Hospital in Western Nepal. Pak J Pharm Sci 2008;21(1):51-6.
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D et al. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respire Crit Care Med 2003;167:1472-7.
- Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. Occurrence of side effects from anti-tuberculosis drugs in urban nepalese population under dots treatment. Kathmandu Univ J Sci Eng Technol 2005 [cited 2017 Aug 31];(1). Available from: http://www.ku.edu.np/kuset/aej/dinesh.pdf
- Daphne Y, Marthe P. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Resp Crit Care Med 2003;167:1472-7.
- Zierski M, Bek E. Side-Effects of Drug Regimens Used in Short-Course Chemotherapy for Pulmonary Tuberculosis: A Controlled Clinical Study. Tuberc 1980;61:41–9.
How to Cite This Article
Vancouver
H A. Adverse effects of first line anti-tubercular drugs on patients taking directly observed treatment short course chemotherapy [Internet]. IP Indian J Immunol Respir Med. 2019 [cited 2025 Oct 13];4(2):128-133. Available from: https://doi.org/10.18231/j.ijirm.2019.029
APA
H, A. (2019). Adverse effects of first line anti-tubercular drugs on patients taking directly observed treatment short course chemotherapy. IP Indian J Immunol Respir Med, 4(2), 128-133. https://doi.org/10.18231/j.ijirm.2019.029
MLA
H, Arjun. "Adverse effects of first line anti-tubercular drugs on patients taking directly observed treatment short course chemotherapy." IP Indian J Immunol Respir Med, vol. 4, no. 2, 2019, pp. 128-133. https://doi.org/10.18231/j.ijirm.2019.029
Chicago
H, A.. "Adverse effects of first line anti-tubercular drugs on patients taking directly observed treatment short course chemotherapy." IP Indian J Immunol Respir Med 4, no. 2 (2019): 128-133. https://doi.org/10.18231/j.ijirm.2019.029